Physician profile
Aline Arif
NPI 1801457593
$1,598.82
in general payments reported to CMS, 2019-2025
15 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what 82% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.68 · 2024: $154 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,559 · Education: $28.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,558.91 |
| Education | $28.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $242.16 | 2024-2025 | Zerbaxa, Recarbrio |
| Gilead Sciences, INC. | $233.20 | 2024-2025 | Biktarvy, Veklury |
| Paratek Pharmaceuticals, INC. | $220.10 | 2024-2025 | Nuzyra |
| Abbvie INC. | $210.19 | 2025 | |
| Viiv Healthcare Company | $163.34 | 2025 | Dovato, Cabenuva |
| Shionogi INC | $162.43 | 2024-2025 | Fetroja |
| Insmed, INC. | $73.75 | 2024-2025 | Brinsupri, Arikayce |
| Melinta Therapeutics, LLC | $64.79 | 2025 | Kimyrsa, Rezzayo, Orbactiv |
| La Jolla Pharmaceutical Company | $60.94 | 2024-2025 | Xacduro, Zevtera |
| Invivyd INC | $53.07 | 2025 | Pemgarda |
| Theratechnologies INC. | $38.27 | 2025 | Egrifta, Trogarzo |
| Biomerieux INC | $25.00 | 2025 | Filmarray Torch Module |
| Emd Serono, INC. | $24.66 | 2025 | |
| Astellas Pharma US INC | $15.24 | 2025 | Cresemba |
| Astrazeneca Pharmaceuticals LP | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aline Arif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.